Palatin Technologies(NASDAQ) PTN

Palatin develops medicines for conditions like low sexual desire and chronic inflammation. Its products help women with sexual health issues and people with inflammatory diseases. The company focuses on treatments that target specific body receptors to improve health outcomes.

What’s in the Medicine Cabinet?

• Vyleesi (bremelanotide): Treatment for low sexual desire in premenopausal women; 100% of product revenue before December 2023 sale.
• PL8177: Oral therapy for inflammatory bowel diseases, targeting people with chronic gut inflammation.
• PL9643: Eye drop for dry eye disease, aimed at patients with chronic eye discomfort.
• PL3994: Investigational drug for heart and blood vessel conditions, focused on cardiovascular patients.
• PL5028: Experimental treatment for heart and tissue scarring diseases, targeting those with cardiac or fibrotic issues.

Growth Moves: Not Just a One-Trick Pony

• Sold Vyleesi rights to Cosette Pharmaceuticals in December 2023 for upfront and milestone payments.
• Partnered with Kwangdong for Vyleesi commercialization in Korea (prior to asset sale).
• Expanded pipeline with new clinical programs in obesity, gut, and eye diseases from 2024 onward.
• Raised capital through equity offerings in 2024 and 2025 to fund research and operations.

Why Palatin Catches the Eye

Palatin specializes in drugs that act on the melanocortin receptor system, a key body signaling pathway. The company keeps a small team and outsources manufacturing and commercialization to partners. Its business model relies on research, asset sales, and licensing deals to fund new drug development.

Five Things You Need to Know

• Product revenue was $0 for the nine months ended March 2025 after the Vyleesi sale, down 100% year-on-year.
• Net loss improved to $(15.1) million for nine months ended March 2025, down 29.8% from prior year.
• Cash used in operations was $(17.2) million for nine months ended March 2025, a 31.1% improvement.
• Cash and equivalents were $2.5 million as of March 31, 2025, with liabilities of $10.0 million.

Bottom Line

Palatin has shifted from commercial sales to drug development and licensing. Its future depends on advancing new therapies and securing external funding.